Psychiatric medications produce psychoactive effects similar to recreational substances, a fact often obscured by the assumption that these drugs have disease-specific actions. These psychoactive effects can directly modify disturbing symptoms, but they also carry costs to mental well-being and raise dependence risks, requiring support for withdrawal. The reality that psychoactive effects can alter symptoms independently undermines the idea that psychiatric drugs work by targeting underlying disease processes and affects placebo-controlled trial results. This also challenges the validity of modern diagnostic systems. Extensive research is needed on acute and long-term mental, behavioral, and physical effects during and after consumption and withdrawal to enable informed use.
Adolescents reported more severe psychotic symptoms on the Positive and Negative Syndrome Scale than adults, while no significant difference was found in cannabis exposure or Aberrant Salience Inventory scores. A hierarchical pattern emerged among adult subgroups, with psychotic patients scoring higher than other psychiatric and neurological patients. The findings suggest that aberrant salience, and to a lesser degree cannabis use, may contribute to psychotic symptom severity, particularly during more at-risk developmental phases. The role of cannabis in this relationship remains unclear.